SHINGRIX mechanism of action

SHINGRIX is designed to induce cellular and humoral immune responses to VZV1*

SHINGRIX is the first and only shingles vaccine to combine two components, a non-live antigen with an Adjuvant System.1,2*

Non-live Antigen/Adjuvant System icon Non-live Antigen/Adjuvant System icon

VZV = varicella zoster virus.
* Clinical significance has not been established.

Learn more about the design of SHINGRIX

Discover the components and the mechanism of action of SHINGRIX.

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372(22):2087–2096.
  3. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  4. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24